Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Stereotaxis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STXS's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: STXS exceeded the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: STXS exceeded the US Market which returned 20.1% over the past year.
Price Volatility Vs. Market
How volatile is Stereotaxis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWe Think Stereotaxis (NYSEMKT:STXS) Can Afford To Drive Business Growth
1 month ago | Simply Wall StDid The Underlying Business Drive Stereotaxis's (NYSEMKT:STXS) Lovely 641% Share Price Gain?
2 months ago | Simply Wall StBefore You Buy Stereotaxis, Inc. (NYSEMKT:STXS), Consider Its Volatility
Is Stereotaxis undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: STXS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: STXS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate STXS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: STXS is overvalued based on its PB Ratio (12.4x) compared to the US Medical Equipment industry average (4.1x).
How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stereotaxis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Stereotaxis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Stereotaxis competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Stereotaxis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STXS is currently unprofitable.
Growing Profit Margin: STXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STXS is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).
Return on Equity
High ROE: STXS has a negative Return on Equity (-14.2%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Stereotaxis's financial position?
Financial Position Analysis
Short Term Liabilities: STXS's short term assets ($38.0M) exceed its short term liabilities ($11.2M).
Long Term Liabilities: STXS's short term assets ($38.0M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: STXS is debt free.
Reducing Debt: STXS currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Inventory Level: STXS has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if STXS's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 16.4% each year
What is Stereotaxis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Fischel (32yo)
Mr. David Leo Fischel, CFA, CPA has been the Chairman of Stereotaxis, Inc. since February 3, 2017 and has been its Chief Executive Officer since February 3, 2017. Mr. Fischel is a Principal and primary por ...
|CEO & Chairman||3yrs||US$58.50k||0.030% $85.0k|
|Chief Legal Officer||1.3yrs||US$218.67k||no data|
|Chief Financial Officer||0.3yrs||no data||0.0050% $14.1k|
|Chief Medical Officer||7.5yrs||no data||no data|
|Chief Development Advisor||12.1yrs||no data||no data|
Experienced Management: STXS's management team is considered experienced (3 years average tenure).
|CEO & Chairman||3yrs||US$58.50k||0.030% $85.0k|
|Independent Director||3.4yrs||US$58.50k||0.50% $1.4m|
|Independent Director||3.4yrs||US$58.50k||9.34% $26.2m|
|Independent Director||14.8yrs||US$58.50k||0.18% $492.2k|
|Lead Independent Director||5yrs||US$58.50k||0.38% $1.1m|
|Independent Director||1.7yrs||US$39.48k||no data|
Experienced Board: STXS's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.5%.
Stereotaxis, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Stereotaxis, Inc.
- Ticker: STXS
- Exchange: AMEX
- Founded: 1990
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$280.841m
- Shares outstanding: 66.08m
- Website: https://www.stereotaxis.com
Number of Employees
- Stereotaxis, Inc.
- 4320 Forest Park Avenue
- Suite 100
- St. Louis
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|STXS||AMEX (NYSE MKT LLC)||Yes||Common Shares||US||USD||Aug 2004|
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company’s disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 23:58|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.